Investigators extend their follow-up to 13 years.
Pediatric-onset multiple sclerosis (POMS) is believed to have a more favorable prognosis than adult-onset MS in terms of physical disability but also to have concerning implications for cognitive disability, adolescent development, and socioprofessional attainment (NEJM JW Neurol May 2022 and Ann Neurol 2022; 91:483).
To provide more information on cognitive outcomes of POMS, investigators conducted follow-up testing at a mean of 13 years in 33 patients with POMS from their original longitudinal cohort of 63. Cognitive testing was performed at regular intervals, and results were converted into a cognitive z score.
Cognition declined between baseline and year 2. While the cognitive score improved between years 2 and 5, it did not return to bas…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)